Figure 6.

Cetuximab treatment prevents relapses of two PDX models expressing L858R-EGFR but a third model expressing Del19-EGFR does not respond to the antibody

NSG mice were pre-implanted with tumor fragments derived from three different PDX models: TM00199 (PDX1, L858R-EGFR) (A), TM00253 (PDX2, L858R-EGFR) (B), and TM00193 (E746_A750 Del19-EGFR) (C). Once tumors reached approximately 500 mm³, mice were treated for 5 weeks (A and B) or 3 weeks (C), as indicated by the gray areas. Shown are tumor volumes corresponding to individual mice. The drugs were administered as follows: cetuximab (0.2 mg/intraperitoneal injection), twice a week, or TKIs, either erlotinib (50 mg/kg) or osimertinib (10 mg/kg), which were orally administered daily. Animal numbers per group are indicated (N). Note that each color represents one animal. See also Figure S7.